Biodefense Market - By Product (Vaccines {Anthrax, Smallpox, Botulism}, Biothreat Detection Devices {Samplers, Detectors/Triggering Devices, Identifiers, Assays and Reagents}) & Forecast, 2022-2028

North America held around 41.6% of the biodefense business revenue share in 2021 and is pegged to observe a notable CAGR through 2028 led by the escalating threat of harmful biological materials.

Biodefense industry revenue was valued at around USD 15.6 billion in 2021 and is anticipated to exhibit an 8.7% CAGR between 2022 and 2028 driven by several safety measures initiated by the government across the developed countries.

The vaccines product segment accounted for over 64.5% of the biodefense market share in 2021 owing to their rising production rate to prevent the spread of various viruses.

Biodefense is a combination of several processes and systems that are put in place by customs agents, bioscience laboratories, among other professionals to prevent the usage of dangerous pathogens and toxins.